Follow-up of asymptomatic HTLV-I carriers among blood donors in Kyushu, Japan

Tokudome, Shinkan; Maeda, Yoshiaki; Fukada, Kazuhiro; Teshima, Daiichiro; Asakura, Takeshi; Sueoka, Eizaburo; Motomura, Yotaro; Kusumoto, Yukihiko; Imamura, Yoichi; Kiyokawa, Tetsuyuki

doi:10.1007/bf00053124

Cited by 7 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 8 , 9 , 10 Their association is still controversial, since several studies have not reported an increased risk. 40 , 41 However, one of these studies with no positive results may have had selection bias resulting from the healthy donor effect, and the other had limited statistical power due to small number of subjects and short follow-up period. The present association among combined subjects from the mainland and Amami island regions was not significant, though the statistical power was relatively low in the mainland.…”

Section: Discussionmentioning

confidence: 99%

Interactions between inflammatory gene polymorphisms and HTLV-I infection for total death, incidence of cancer, and atherosclerosis-related diseases among the Japanese population

Kairupan¹,

Ibusuki²,

Kheradmand³

et al. 2017

Journal of Epidemiology

View full text Add to dashboard Cite

BackgroundAn increased risk of total death owing to human T-lymphotropic virus type-I (HTLV-I) infection has been reported. However, its etiology and protective factors are unclear. Various studies reported fluctuations in immune-inflammatory status among HTLV-I carriers. We conducted a matched cohort study among the general population in an HTLV-I-endemic region of Japan to investigate the interaction between inflammatory gene polymorphisms and HTLV-I infection for total death, incidence of cancer, and atherosclerosis-related diseases.MethodWe selected 2180 sub-cohort subjects aged 35–69 years from the cohort population, after matching for age, sex, and region with HTLV-I seropositives. They were followed up for a maximum of 10 years. Inflammatory gene polymorphisms were selected from TNF-α, IL-10, and NF-κB1. A Cox proportional hazard model was used to estimate the hazard ratio (HR) and the interaction between gene polymorphisms and HTLV-I for risk of total death and incidence of cancer and atherosclerosis-related diseases.ResultsHTLV-I seropositivity rate was 6.4% in the cohort population. The interaction between TNF-α 1031T/C and HTLV-I for atherosclerosis-related disease incidence was statistically significant (p = 0.020). No significant interaction was observed between IL-10 819T/C or NF-κB1 94ATTG ins/del and HTLV-I. An increased HR for total death was observed in the Amami island region, after adjustment of various factors with gene polymorphisms (HR 3.03; 95% confidence interval, 1.18–7.77).ConclusionThe present study found the interaction between TNF-α 1031T/C and HTLV-I to be a risk factor for atherosclerosis-related disease. Further follow-up is warranted to investigate protective factors against developing diseases among susceptible HTLV-I carriers.

show abstract

Section: Discussionmentioning

confidence: 99%

Interactions between inflammatory gene polymorphisms and HTLV-I infection for total death, incidence of cancer, and atherosclerosis-related diseases among the Japanese population

Kairupan¹,

Ibusuki²,

Kheradmand³

et al. 2017

Journal of Epidemiology

View full text Add to dashboard Cite

show abstract

“…To date, there are a total of six cohort analyses based in Japan that document the incidence of ATLL among HTLV-1 carriers, and confirm that male carriers have about a 3-5 fold higher risk of developing ATLL than female carriers (Tokudome et al 1991;Iwata et al, 1994;Arisawa et al, 2000Arisawa et al, , 2003Arisawa et al, , 2006Hisada et al, 2001). It is worth noting that because HTLV-1-seropositivity is part of the diagnosis of ATLL, relative risks for ATLL can not be calculated (see Table 2.2 available at http://monographs.iarc.fr/ENG/ Monographs/vol100B/100B-07-Table2.2.pdf).…”

Section: 1 1 Htlv-1 Infection and Atllmentioning

confidence: 98%

A review of human carcinogens—Part B: biological agents

Bouvard

Baan

Straif

et al. 2009

The Lancet Oncology

2,510

1,958

View full text Add to dashboard Cite

“…In a review of the literature, we found only three studies that tried to look at the prevalence of malignancy, most of them ATLL, in cohorts of blood donors infected with HTLV-1. The prevalence of ATLL in American HTLV-1 carrier blood donors was 0-2.7% [6][7][8] (Table 2).…”

Section: Discussionmentioning

confidence: 99%